Zacks Investment Research on MSN
Can Novo Nordisk's Aggressive Deal-Making Offset Semaglutide Reliance?
Novo Nordisk NVO continues to derive the bulk of its revenue from its blockbuster semaglutide (GLP-1 RA) therapies, Wegovy for obesity and Ozempic for type II diabetes (T2D). Together, the drugs ...
MarketBeat on MSN
Novo Nordisk's Akero Therapeutics Buy Targets Eli Lilly's Lead
Novo Nordisk A/S (NYSE: NVO) recently announced plans to acquire Akero Therapeutics. The deal, which is valued at around $4.7 ...
Novo Nordisk has struck a deal to buy Akero Therapeutics for up to $5.2 billion, teeing up a showdown with Roche and others in a blockbuster liver disease market. Akero confirmed its status as a key ...
LONDON, Oct 9 (Reuters Breakingviews) - Novo Nordisk (NOVOb.CO), opens new tab is doubling down on obesity. On Thursday, opens new tab, the $264 billion maker of weight loss drugs Ozempic and Wegovy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback